Using UPLC-MS/MS for Workplace Drug Testing

Significance of the Topic

Workplace drug testing in safety-critical industries requires rapid, accurate methods to screen large sample numbers while minimizing false positives. Traditional immunoassays lack compound specificity, often leading to unnecessary confirmatory tests. A sensitive UPLC-MS/MS approach addresses these limitations, supporting safer work environments and reducing downstream costs.

Objectives and Study Overview

The study aimed to develop and validate a simple, high-throughput UPLC-MS/MS method to screen 21 common drugs and metabolites in urine by direct dilution, enabling semi-quantitative results below current cut-offs and improving overall testing efficiency.

Methodology

Sample preparation consisted of adding a deuterated internal standard mixture to 200 µL of urine, vortex mixing, centrifugation, and dilution with water. Chromatographic separation used an ACQUITY UPLC BEH C18 column (2.1 × 100 mm, 1.7 µm) at 40 °C with a 7-minute gradient from 2% to 95% acetonitrile (0.1% formic acid) at 400 µL/min. Detection employed ESI with polarity switching on a Xevo TQD operating at 150 °C source and 500 °C desolvation temperatures. Multiple reaction monitoring (MRM) transitions were optimized for each analyte and matched to specific internal standards.

Instrumentation Used

• Waters ACQUITY UPLC I-Class system
• Waters Xevo TQD triple quadrupole mass spectrometer

Main Results and Discussion

Calibration curves over 1–500 ng/mL (1–250 ng/mL for select analytes) showed R² > 0.995. Limits of detection ranged from 0.25 to 4 ng/mL and LLOQs from 0.5 to 5 ng/mL. Matrix effects were <20% for most compounds. Interday accuracy and precision at three QC levels met acceptance criteria (<15% bias and RSD). Analysis of 114 authentic urine samples confirmed method agreement with GC-MS, detected analytes below immunoassay cut-offs, and eliminated false positives found by immunoassay.

Benefits and Practical Applications

• High throughput: 7 min runtime per injection with simple dilution
• Comprehensive panel: 21 analytes in one run
• Reduced false positives by compound-specific detection
• Minimal sample preparation and robust performance

Future Trends and Potential Applications

Future developments may include automated sample handling, expansion to emerging drug classes, integration of high-resolution MS for non-targeted screening, portable MS platforms for on-site testing, and advanced data analytics or AI-driven interpretation to further streamline workplace drug monitoring.

Conclusion

The validated UPLC-MS/MS method offers a rapid, reliable, and sensitive solution for workplace drug screening, achieving excellent correlation with established GC-MS confirmatory assays while simplifying workflows and improving detection capabilities.

References

• 1. Kazanga I et al. Prevalence of drug abuse among workers: Strengths and pitfalls of the recent Italian workplace Drug Testing (WPDT) legislation. Forensic Science International. 2012;215(1-3):46–50.